Stocks to Buy based on the Best Stock Market Research
Pfizer has the only FDA-approved drug in a class called CCR5 antagonists. A "cure for HIV" will most likely focus on CCR5, top scientist say.
If not by Pfizer's maraviroc, then a next-generation version of it could be part of the long-awaited cure. This isn't like fusion energy, where the breakthrough is always 30 years away. In this case, a conservative bet is 10 years. Actually, a cure for HIV has been demonstrated in one patient, which amounts to a proof of concept.
Mutations in human genes cause muscular dystrophy, but a mutation in the CCR5 gene has a huge health benefit: people with it are almost completely resistant to HIV infection. Since that discovery was made in 1996, Pfizer and other pharmaceutical companies have become focused on developing a treatment that mimics the effects of a CCR5 mutation.
Here is a summary I wrote that describes the race for a cure for HIV -- http://bit.ly/OGbWQn